Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA

International Journal of Chronic Obstructive Pulmonary Disease ◽

10.2147/copd.s196383 ◽

2019 ◽

Vol Volume 14 ◽

pp. 531-546 ◽

Cited By ~ 6

Author(s):

Dave Singh ◽

Leonardo M Fabbri ◽

Stefano Vezzoli ◽

Stefano Petruzzelli ◽

Alberto Papi

Keyword(s):

Triple Therapy ◽

Clinically Important Deterioration

Download Full-text

When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment

International Journal of Chronic Obstructive Pulmonary Disease ◽

10.2147/copd.s279482 ◽

2020 ◽

Vol Volume 15 ◽

pp. 3375-3384

Author(s):

Wen-Chien Cheng ◽

Biing-Ru Wu ◽

Wei-Chih Liao ◽

Chih-Yu Chen ◽

Wei-Chun Chen ◽

...

Keyword(s):

Triple Therapy ◽

Clinically Important Deterioration ◽

Deterioration Assessment

Download Full-text

Preventing Clinically Important Deterioration (CID) of COPD with Single-inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol: A Prospective Analysis of the IMPACT Trial

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2438 ◽

2019 ◽

Author(s):

M.K. Han ◽

G.J. Criner ◽

M.T. Dransfield ◽

D.M.G. Halpin ◽

C.E. Jones ◽

...

Keyword(s):

Triple Therapy ◽

Prospective Analysis ◽

Fluticasone Furoate ◽

Clinically Important Deterioration ◽

The Impact

Download Full-text

Clinically important deterioration in advanced COPD patients using single inhaler triple therapy: results from the FULFIL study

10.1183/1393003.congress-2017.pa3248 ◽

2017 ◽

Author(s):

Ian Naya ◽

Helen Barnacle ◽

Ruby Birk ◽

Noushin Brealey ◽

Maggie Tabberer ◽

...

Keyword(s):

Triple Therapy ◽

Copd Patients ◽

Clinically Important Deterioration

Download Full-text

The key to successful eradication of H. pylori, using lansoprazole or rabeprazole based triple therapy, is clarithromycin resistance, not CYP2C19 polymorphism

Gastroenterology ◽

10.1016/s0016-5085(01)82921-8 ◽

2001 ◽

Vol 120 (5) ◽

pp. A587-A587

Author(s):

I MIKI ◽

N AOYAMA ◽

T SAKAI ◽

D SHIRASAKA ◽

S EBARA ◽

...

Keyword(s):

Triple Therapy ◽

Clarithromycin Resistance ◽

Cyp2c19 Polymorphism ◽

H Pylori

Download Full-text

H pylori eradication with PPI-triple therapy in clinical practice: Factors of failure

Gastroenterology ◽

10.1016/s0016-5085(01)82906-1 ◽

2001 ◽

Vol 120 (5) ◽

pp. A584-A584

Author(s):

J DELCHIER ◽

F RUODOTTHORAVAL ◽

A COURILLONMALLET ◽

H LAMOULIATTE ◽

J BRETAGNE ◽

...

Keyword(s):

Clinical Practice ◽

Triple Therapy ◽

H Pylori

Download Full-text

On-treatment and projected sustained viral responses with boceprevir-based triple therapy in previous treatment-failure HCV patients with advanced fibrosis or cirrhosis. Interim analysis of the Hungarian named patient program cohort

Zeitschrift für Gastroenterologie ◽

10.1055/s-0033-1347476 ◽

2013 ◽

Vol 51 (05) ◽

Author(s):

B Hunyady ◽

M Abonyi ◽

K Csefkó ◽

A Haragh ◽

G Horváth ◽

...

Keyword(s):

Treatment Failure ◽

Triple Therapy ◽

Interim Analysis ◽

Previous Treatment ◽

Advanced Fibrosis ◽

Viral Responses

Download Full-text

Real world experience in 150 genotype 1 HCV patients with triple therapy: severe adverse events and high rates of virological failure in cirrhotic patients with portal hypertension (platelets < 100.000/nl and albumine < 40 g/l)

Zeitschrift für Gastroenterologie ◽

10.1055/s-0033-1352750 ◽

2013 ◽

Vol 51 (08) ◽

Author(s):

J Petersen ◽

K Voelker ◽

K Olah ◽

K Matschenz ◽

H Wolski ◽

...

Keyword(s):

Portal Hypertension ◽

Adverse Events ◽

Triple Therapy ◽

Virological Failure ◽

Real World ◽

Genotype 1 ◽

Cirrhotic Patients ◽

Severe Adverse Events

Download Full-text

High virologic response rate at End of Treatment (EOT) following triple therapy of previously untreated HCV Genotype 1 (G1) infection with boceprevir in German real-life

Zeitschrift für Gastroenterologie ◽

10.1055/s-0034-1386302 ◽

2014 ◽

Vol 52 (08) ◽

Author(s):

P Buggisch ◽

H Löhr ◽

G Teuber ◽

H Steffens ◽

M Kraus ◽

...

Keyword(s):

Triple Therapy ◽

Response Rate ◽

Real Life ◽

Virologic Response ◽

Genotype 1 ◽

Hcv Genotype ◽

End Of Treatment ◽

Hcv Genotype 1 ◽

Virologic Response Rate

Download Full-text

Baseline predictors of an early virologic response (EVR) in previously untreated patients undergoing boceprevir (BOC) triple therapy for HCV genotype 1 infection in German real-life

Zeitschrift für Gastroenterologie ◽

10.1055/s-0034-1397212 ◽

2015 ◽

Vol 53 (01) ◽

Author(s):

P Buggisch ◽

H Löhr ◽

G Teuber ◽

H Steffens ◽

M Kraus ◽

...

Keyword(s):

Triple Therapy ◽

Real Life ◽

Virologic Response ◽

Genotype 1 ◽

Early Virologic Response ◽

Hcv Genotype ◽

Hcv Genotype 1

Download Full-text

Baseline gamma-GT levels within the normal range predict high virologic response rates in treatment-naïve patients undergoing boceprevir triple therapy for HCV genotype 1 (G1) infection

Zeitschrift für Gastroenterologie ◽

10.1055/s-0034-1397211 ◽

2015 ◽

Vol 53 (01) ◽

Author(s):

P Buggisch ◽

HF Löhr ◽

G Teuber ◽

H Steffens ◽

MR Kraus ◽

...

Keyword(s):

Triple Therapy ◽

Response Rates ◽

Virologic Response ◽

Genotype 1 ◽

Normal Range ◽

Hcv Genotype ◽

Treatment Naïve ◽

Hcv Genotype 1

Download Full-text